In the first quarter, total company revenues declined 2% operationally. This was due primarily to the loss of exclusivity of Viagra in the U.S. in December 2017. By a similar competition for Enbrel in Europe and product supply shortages related to our legacy Hospira products in the U.S. and our production facilities in Puerto Rico. These declines were partially offset by continued strong growth and emerging markets biosimilars globally and many of our anchor brands. I'll begin with a few words about each of our businesses starting with Pfizer innovative health. This business had another solid quarter growing as topline 3% operationally thanks to the continued strength of several of our biggest selling medicines.